Arthritis Research & Therapy

official impact factor 4.36

This article is part of the supplement: Interleukin-6, a pleiotropic cytokine

Highly Access

Interleukin-6: discovery of a pleiotropic cytokine

Tadamitsu Kishimoto

Arthritis Research & Therapy 2006, 8(Suppl 2):S2 doi:10.1186/ar1916

Accesses  

  • Last 30 days: 142 accesses
  • Last 365 days: 1946 accesses
  • All time: 14087 accesses

Cited by

BioMed Central: 4 citations

Research   Open Access

HBV replication is significantly reduced by IL-6

Tzer-Min Kuo, Cheng-po Hu, Ya-Ling Chen, Ming-Hsiang Hong, King-Song Jeng, Chun-Chin T Liang, Mong-Liang Chen, Chungming Chang Journal of Biomedical Science 2009, 16:41 (20 April 2009)

Research   Open Access

Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice

Laurent Savale, Ly Tu, Dominique Rideau, Mohamed Izziki, Bernard Maitre, Serge Adnot, Saadia Eddahibi Respiratory Research 2009, 10:6 (27 January 2009)

Research article   Open Access Highly Accessed

Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept

Dirk Koczan, Susanne Drynda, Michael Hecker, Andreas Drynda, Reinhard Guthke, Joern Kekow, Hans-Juergen Thiesen Arthritis Research & Therapy 2008, 10:R50 (2 May 2008)

Review   Free

Developments in lupus 2006

Arne Hansen, Falk Hiepe, Thomas Dörner Arthritis Research & Therapy 2007, 9:215 (11 July 2007)